Avicanna Inc. (OTCQX: AVCNF) (TSX:AVCN) (FSE:0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, has expanded its research collaboration in field of epilepsy with a new collaboration with the University of Toronto and Dr. Mac Burnham’s research team to explore the efficacy of Avicanna’s proprietary formulations in pre-clinical models for epilepsy.

New research collaboration with University of Toronto

The research collaboration led by Dr. Burnham’s team will explore the efficacy of Avicanna’s drug candidates including AVCN319302 in animal models for epilepsy. In addition, the research collaboration will evaluate the anti-seizure properties of rare cannabinoids in isolation and in combination. Dr. Burnham is a professor emeritus of pharmacology and toxicology at the University of Toronto's Temerty Faculty of Medicine, and is a co-director of EpLink, the Ontario Brain Institute’s …

Full story available on Benzinga.com